Experts in the treatment of multiple sclerosis (MS) offer insights into data presented at the 2021 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.
EP. 1: Real-World Data on Ofatumumab in Patients With MS
An expert discusses real-world data for ofatumumab (Kesimpta; Novartis), the first self-administered anti-CD20 monoclonal antibody, in patients with relapsing multiple sclerosis.
EP. 2: Ofatumumab and the Anti-CD20 Class
An expert discusses takeaways about the anti-CD20 monoclonal antibody class of disease-modifying therapies for patients with relapsing multiple sclerosis through the lens of ofatumumab (Kesimpta; Novartis).
EP. 3: Siponimod’s Efficacy on Secondary Progressive MS
An expert provided context on a subanalysis of the EXPAND study that evaluated the effect of baseline age on the efficacy and safety of siponimod (Mayzent; Novartis) in secondary progressive multiple sclerosis.
EP. 4: Understanding Disease Progression in Older Patients With MS
Le Hua, MD, provided insight on the current knowns and unknowns about older patients with multiple sclerosis, how their disease progresses, and the need for additional research.
EP. 5: Research to Further Improve Treatment Optimization in MS
An expert provides the necessary steps needed to bolster accuracy of prescribed disease-modifying therapies for MS and do away with outdated trial-and-error approaches.
2 Clarke Drive Cranbury, NJ 08512